Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3 Breast Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Gastrointestinal Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Adenocarcinoma 1

Interventions

Oxaliplatin 30 Gemcitabine 28 Fluorouracil 27 Capecitabine 22 Leucovorin 19 pembrolizumab 15 130-nm albumin-bound paclitaxel 13 Irinotecan 12 Cisplatin 11 Bevacizumab 11 Albumin-Bound Paclitaxel 11 Paclitaxel 10 Ramucirumab 8 Radiotherapy 8 Docetaxel 8 Nivolumab 7 trastuzumab deruxtecan 6 Cyclophosphamide 6 Taxes 5 Drug Therapy 5 durvalumab 4 Trastuzumab 4 Metformin 4 zolbetuximab 3 spartalizumab 3 folfirinox 3 cemiplimab 3 XELOX 3 Surgical Procedures, Operative 3 Sorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × ipatasertib × Gastrointestinal × Clear all

NCT04739202 2026-06-09

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡